Plexitome™ Officially Launches in Strategic Partnership with VEO Ophthalmics

Breakthrough device offers a more precise approach to treating recurrent corneal erosions and large cornea abrasions

WEST CHESTER, Ohio, Aug. 28, 2025 /PRNewswire/ -- Plexitome™, a groundbreaking new device for anterior stromal puncture (ASP), is now available through a strategic partnership between Plexitome Medical and VEO Ophthalmics, an industry leader of innovative ophthalmic technologies. Designed to provide unmatched precision and consistency, Plexitome™ is poised to become a game-changing option in the treatment of Recurrent Corneal Erosion (RCE) and other epithelial basement membrane dystrophies (EBMD).

Unlike traditional tools, Plexitome™ features a 6.2 mm diameter disc array with approximately 675 precisely engineered micro-spikes, delivering controlled and uniform puncture depth through Bowman's layer of the cornea—without creating optically evident anterior stromal scarring. With up to 3,375 individual epithelial attachment points created over five imprints, the device enhances corneal healing and reduces long-term recurrence rates.

"Plexitome™ represents a significant step forward in the management of corneal disorders, particularly in the optical axis. The device was engineered to improve outcomes while eliminating the unpredictability and limitations of manual ASP," said Dr. Edward Chaum, Founder and Chief Medical Officer at Plexitome Medical. "VEO Ophthalmics has a history of bringing innovative products to market, and we are excited to partner with them for our commercialization strategy."

"Plexitome Medical has developed a truly innovative approach to treating RCE and large corneal abrasions," Said Ron Gilliland, CEO of VEO Ophthalmics. "Plexitome™ is sure to reinvent how cornea specialists utilize anterior stromal puncture. We are pleased to work together with Plexitome Medical to bring this new technology to cornea specialists and their patients."

In clinical use, Plexitome™ has demonstrated the ability to penetrate Bowman's layer through both debrided and loose, intact epithelium, creating stable epithelial attachments even in areas where traditional ASP methods fall short. It may also shorten healing times for large corneal abrasions and help mitigate the risk of recurrence in erosive conditions.

VEO Ophthalmics will lead the commercial rollout of Plexitome™, providing access, training and support to corneal specialists and surgical teams across the U.S., and globally.

For more information or to request a product demonstration, visit the website here.

About Plexitome™
Plexitome™ is a patented micro-spike array device developed to deliver safe, precise, and uniform anterior stromal puncture for the treatment of recurrent corneal erosion and EBMD. Its innovative design allows effective treatment in the optical axis, without the scarring associated with traditional ASP.

VEO Ophthalmics
VEO Ophthalmics, LLC, is a leader in ophthalmics surgical technologies. VEO focuses on improving patient care by partnering with leading ophthalmic surgeons to develop innovative technologies. Close relationships with ophthalmic healthcare customers and business partners help VEO ensure that its products and service experience meet the highest standards.

View original content to download multimedia:https://www.prnewswire.com/news-releases/plexitome-officially-launches-in-strategic-partnership-with-veo-ophthalmics-302541164.html

SOURCE Plexitome